Influx Healthtech Ltd
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Mar 2029 (P) | |
|---|---|---|---|---|---|
| Asset Turnover Times |
|
||||
| Installed Capacity - Cosmetics & Ayurvedic Kg per day |
|||||
| Installed Capacity - Nutraceuticals Kg per day |
|||||
| Installed Capacity - Pet Supplements & Homecare Kg per day |
|||||
| Number of Clients Count |
|||||
| Number of Products Count |
|||||
| Order Book/Revenue Target (Internal) INR Cr |
|||||
| Capacity Utilization - Cosmetics & Ayurvedic % |
|||||
| Capacity Utilization - Nutraceuticals % |
|||||
| Capacity Utilization - Pet Supplements & Homecare % |
|||||
| Export Countries Count |
|||||
| Permanent Employees Count ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Press Release
13 April 2026 - Board proposes reallocation of ₹1,009.31 lakh IPO proceeds to expand Plot No. 59; shareholder approval pending.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
13 April 2026 - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.
-
Copy of Newspaper Publication
7 April 2026 - Newspaper ads published April 7, 2026 for corrigendum to April 6 postal ballot notice.
-
Corrigendum
6 April 2026 - Postal ballot corrigendum dated April 6, 2026 appoints Mr. Nayan P. Pitroda as scrutinizer.
-
Copy of Newspaper Publication
2 April 2026 - PAS-1 newspaper ads published April 2, 2026 for postal ballot on varying prospectus objects.
Annual reports
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025TranscriptAI SummaryPPT
Business Profile[1]
The company operates as a Contract Development and Manufacturing Organization (CDMO) catering to B2B clients in nutraceuticals, cosmetics, ayurvedic/herbal products, veterinary feed supplements, and homecare products.
Its core competency is offering end-to-end manufacturing services, including product formulation, development, regulatory support, and commercialization.